

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 7.4 | 81.6 | (29.8-177.6) | Male | 11 | 5.1 | 214.6 | (107-384) |
| Female | 2 | 2.5 | nc | (nc-nc) | Female | 3 | 3.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) | Female | 0 | 1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 43 | 30.5 | 140.9 | (101.9-189.8) | Female | 3 | 3.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 2 | 3.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 11 | 8.8 | 125.1 | (62.4-223.9) | Female | 5 | 2.7 | 186.6 | (60.1-435.5) |
| Female | 9 | 8 | 113.2 | (51.6-214.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 2.5 | nc | (nc-nc) |
| Male | 2 | 2.2 | nc | (nc-nc) | Female | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 40 | 31.6 | 126.6 | (90.4-172.4) |
| Male | 0 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.5 | nc | (nc-nc) | Male | 1 | 1.8 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 1 | nc | (nc-nc) |
| Male | 2 | 4.4 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 2.3 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 1 | 2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 9 | 5.8 | 155.5 | (70.9-295.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 2.9 | nc | (nc-nc) | Female | 6 | 7.1 | 85 | (31-184.9) |
| Female | 2 | 2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 99 | 107 | 92.6 | (75.2-112.7) |
| Male | 2 | 2.7 | nc | (nc-nc) | Female | 111 | 99 | 112.1 | (92.2-135) |
| Female | 0 | 0.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 7 | 14 | 50.2 | (20.1-103.4) | | | | | |
| Female | 11 | 13.4 | 82.2 | (41-147) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 20 | 20.3 | 98.6 | (60.2-152.2) | Male | 26 | 13.4 | 193.4 | (126.3-283.5) |
| Female | 9 | 8.2 | 110.2 | (50.3-209.1) | Female | 17 | 11.6 | 147.1 | (85.7-235.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 3.9 | nc | (nc-nc) | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) | Female | 4 | 3.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 13 | 11.7 | 110.9 | (59-189.6) |
| Female | 92 | 87.8 | 104.7 | (84.4-128.5) | Female | 8 | 10.6 | 75.2 | (32.4-148.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 3.1 | nc | (nc-nc) | Male | 17 | 9.2 | 183.9 | (107.1-294.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 25 | 23.4 | 106.8 | (69.1-157.7) | Female | 8 | 8 | 100.6 | (43.3-198.2) |
| Female | 28 | 26.1 | 107.4 | (71.4-155.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 6 | 6.8 | 88.7 | (32.4-193.2) |
| Male | 5 | 5.6 | 88.6 | (28.5-206.7) | Female | 8 | 7.9 | 101.4 | (43.6-199.7) |
| Female | 2 | 1.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 83 | 79.7 | 104.1 | (82.9-129.1) |
| Male | 3 | 1.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1.3 | nc | (nc-nc) | Male | 4 | 4.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 3.2 | nc | (nc-nc) |
| Male | 11 | 11.2 | 97.9 | (48.8-175.2) | <u>Testis</u> | | | | |
| Female | 2 | 6.9 | nc | (nc-nc) | Male | 1 | 2.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 3.1 | nc | (nc-nc) | Male | 7 | 4.9 | 142.3 | (57-293.2) |
| Female | 0 | 1 | nc | (nc-nc) | Female | 24 | 15.8 | 151.9 | (97.3-226) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 7.8 | 89.8 | (36-185) | Female | 13 | 20.3 | 64.2 | (34.1-109.7) |
| Female | 5 | 6.3 | 79.4 | (25.6-185.3) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 278 | 279 | 99.6 | (88.3-112.1) |
| Male | 2 | 6.7 | nc | (nc-nc) | Female | 306 | 298.2 | 102.6 | (91.4-114.8) |
| Female | 5 | 2.4 | 207.3 | (66.8-483.8) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 31 | 37.4 | 82.8 | (56.3-117.6) | | | | | |
| Female | 44 | 41.6 | 105.9 | (76.9-142.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 91 | 100.6 | 90.5 | (72.8-111.1) | Male | 69 | 63.3 | 109.1 | (84.9-138) |
| Female | 37 | 36.9 | 100.3 | (70.6-138.3) | Female | 64 | 51.2 | 125 | (96.2-159.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 21 | 18.2 | 115.2 | (71.3-176.1) | Male | 18 | 17.8 | 101.3 | (60-160) |
| Female | 21 | 15.7 | 133.4 | (82.6-204) | Female | 11 | 14.8 | 74.5 | (37.1-133.3) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 3.1 | nc | (nc-nc) | Male | 57 | 56.1 | 101.6 | (77-131.7) |
| Female | 479 | 378.8 | 126.5 | (115.4-138.3) | Female | 58 | 47.6 | 122 | (92.6-157.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 12 | 13.2 | 90.6 | (46.8-158.3) | Male | 45 | 41.4 | 108.8 | (79.3-145.5) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 87 | 112.4 | 77.4 | (62-95.5) | Female | 41 | 34.8 | 117.9 | (84.6-159.9) |
| Female | 98 | 117 | 83.7 | (68-102) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 34 | 32.8 | 103.8 | (71.9-145) |
| Male | 11 | 26.3 | 41.8 | (20.8-74.7) | Female | 43 | 35.8 | 120.2 | (87-162) |
| Female | 6 | 7.4 | 80.8 | (29.5-175.9) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 365 | 360.9 | 101.1 | (91-112.1) |
| Male | 1 | 7.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 4 | 6.5 | nc | (nc-nc) | Male | 16 | 23.6 | 67.9 | (38.8-110.3) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 14 | 14.5 | 96.9 | (52.9-162.5) |
| Male | 48 | 51 | 94 | (69.3-124.7) | <u>Testis</u> | | | | |
| Female | 23 | 30.5 | 75.5 | (47.8-113.2) | Male | 12 | 11.3 | 106.6 | (55-186.2) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 14.3 | 70 | (33.5-128.7) | Male | 31 | 21.8 | 142 | (96.5-201.6) |
| Female | 2 | 4.5 | nc | (nc-nc) | Female | 87 | 69 | 126.1 | (101-155.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 43 | 38.3 | 112.3 | (81.3-151.3) | Female | 80 | 86.7 | 92.3 | (73.2-114.9) |
| Female | 25 | 28.7 | 87.2 | (56.4-128.7) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 1174 | 1312.8 | 89.4 | (84.4-94.7) |
| Male | 23 | 30.3 | 76 | (48.2-114.1) | Female | 1414 | 1314.9 | 107.5 | (102-113.3) |
| Female | 10 | 10.7 | 93.4 | (44.7-171.7) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 117 | 180 | 65 | (53.7-77.9) | | | | | |
| Female | 155 | 185.9 | 83.4 | (70.8-97.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 9.2 | 65.5 | (23.9-142.6) | Male | 11 | 7.6 | 145.6 | (72.6-260.6) |
| Female | 3 | 2.2 | nc | (nc-nc) | Female | 6 | 4.1 | 146.7 | (53.6-319.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.6 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) | Female | 1 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 9 | 6.5 | 137.8 | (62.9-261.6) |
| Female | 51 | 31.6 | 161.3 | (120.1-212) | Female | 2 | 3.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.3 | nc | (nc-nc) | Male | 4 | 5.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 14 | 12.3 | 114 | (62.3-191.3) | Female | 0 | 2.7 | nc | (nc-nc) |
| Female | 8 | 7.3 | 109.2 | (47-215.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 3 | nc | (nc-nc) | Male | 53 | 43.5 | 121.9 | (91.3-159.5) |
| Female | 2 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 6.7 | 118.6 | (51.1-233.6) | Female | 8 | 7.1 | 111.9 | (48.2-220.5) |
| Female | 1 | 2.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 3 | 1.7 | nc | (nc-nc) | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 2 | 2 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 8 | 3.9 | 206.9 | (89.1-407.7) | Male | 19 | 17.8 | 106.5 | (64.1-166.3) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 6 | 12.1 | 49.5 | (18.1-107.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 19 | 16.5 | 115 | (69.2-179.5) | Male | 7 | 10.3 | 68 | (27.2-140) |
| Female | 10 | 6.9 | 145 | (69.4-266.7) | Female | 5 | 8.7 | 57.4 | (18.5-133.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 2.9 | 169.9 | (54.8-396.6) | Male | 5 | 2.9 | 172.7 | (55.6-402.9) |
| Female | 2 | 2.7 | nc | (nc-nc) | Female | 3 | 2.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 7 | 9.1 | 76.7 | (30.7-158.1) |
| Female | 47 | 63.2 | 74.4 | (54.7-99) | Female | 5 | 8.5 | 58.5 | (18.9-136.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 2.1 | nc | (nc-nc) | Male | 8 | 6.6 | 122 | (52.5-240.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 25 | 18.1 | 138 | (89.3-203.7) | Female | 4 | 6 | nc | (nc-nc) |
| Female | 31 | 21.5 | 144.1 | (97.9-204.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 5.3 | nc | (nc-nc) |
| Male | 12 | 4.3 | 281.2 | (145.1-491.2) | Female | 12 | 6.7 | 178 | (91.9-310.9) |
| Female | 1 | 1.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 54 | 58.3 | 92.7 | (69.6-120.9) |
| Male | 0 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 4 | 3.8 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 6 | 2.7 | 223.1 | (81.5-485.7) |
| Male | 10 | 8.2 | 121.9 | (58.3-224.1) | <u>Testis</u> | | | | |
| Female | 2 | 5.3 | nc | (nc-nc) | Male | 3 | 2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 2.3 | nc | (nc-nc) | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 3 | 0.8 | nc | (nc-nc) | Female | 10 | 10.8 | 92.6 | (44.3-170.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 6.2 | 96.5 | (35.2-210) | Female | 12 | 14.4 | 83.4 | (43-145.6) |
| Female | 5 | 5.2 | 96.3 | (31-224.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 235 | 213.3 | 110.2 | (96.5-125.2) |
| Male | 7 | 4.8 | 144.5 | (57.9-297.7) | Female | 221 | 229.7 | 96.2 | (84-109.8) |
| Female | 2 | 1.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 45 | 29.7 | 151.6 | (110.5-202.8) | | | | | |
| Female | 48 | 34.3 | 140.1 | (103.3-185.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|----------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 36 | 28.2 | 127.8 | (89.5-176.9) | Male | 21 | 18.5 | 113.5 | (70.3-173.6) |
| Female | 16 | 11.4 | 140.7 | (80.4-228.5) | Female | 11 | 15.8 | 69.6 | (34.7-124.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 5.7 | 105.8 | (38.6-230.2) | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) | Female | 5 | 4.5 | 111.1 | (35.8-259.2) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 5 | 0.9 | 560.6 | (180.7-1308.2) | Male | 17 | 16.5 | 103.2 | (60.1-165.2) |
| Female | 117 | 115.9 | 101 | (83.5-121) | Female | 19 | 14.6 | 130 | (78.2-203) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 5 | 4.2 | 119.6 | (38.5-279.1) | Male | 11 | 12.4 | 88.5 | (44.1-158.3) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 30 | 32.6 | 92 | (62.1-131.4) | Female | 10 | 10.6 | 94.3 | (45.1-173.4) |
| Female | 44 | 36.9 | 119.4 | (86.7-160.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 12 | 9.3 | 129.3 | (66.7-225.8) |
| Male | 6 | 7.5 | 79.5 | (29-173.1) | Female | 11 | 11.1 | 99.1 | (49.4-177.3) |
| Female | 1 | 2.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 118 | 103.6 | 113.9 | (94.3-136.4) |
| Male | 4 | 2.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 4 | 2 | nc | (nc-nc) | Male | 4 | 6.8 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 7 | 4.6 | 152.7 | (61.2-314.5) |
| Male | 18 | 15.2 | 118.4 | (70.1-187.1) | <u>Testis</u> | | | | |
| Female | 5 | 9.2 | 54.1 | (17.4-126.3) | Male | 6 | 3.8 | 158.6 | (57.9-345.2) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 4.1 | nc | (nc-nc) | Male | 11 | 6.9 | 160.6 | (80-287.3) |
| Female | 0 | 1.3 | nc | (nc-nc) | Female | 23 | 21.6 | 106.5 | (67.5-159.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 10 | 11.3 | 88.7 | (42.5-163.2) | Female | 18 | 25.6 | 70.2 | (41.6-110.9) |
| Female | 10 | 9.1 | 110.5 | (52.9-203.1) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 401 | 379.5 | 105.7 | (95.6-116.5) |
| Male | 6 | 8.9 | 67.3 | (24.6-146.5) | Female | 408 | 403.2 | 101.2 | (91.6-111.5) |
| Female | 5 | 3.3 | 153.4 | (49.4-358.1) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 40 | 50.5 | 79.2 | (56.6-107.9) | | | | | |
| Female | 56 | 55.4 | 101.1 | (76.4-131.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 17 | 23.8 | 71.4 | (41.6-114.4) | Male | 28 | 17.1 | 164.1 | (109-237.2) |
| Female | 7 | 8.6 | 81.1 | (32.5-167) | Female | 18 | 14.5 | 124.4 | (73.7-196.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 7 | 5.5 | 126.7 | (50.7-261) | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 5 | 4.5 | 112 | (36.1-261.4) | Female | 5 | 3.6 | 140.5 | (45.3-327.9) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 13 | 15 | 86.8 | (46.1-148.4) |
| Female | 99 | 105.2 | 94.1 | (76.5-114.6) | Female | 13 | 12 | 108 | (57.5-184.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 4.2 | nc | (nc-nc) | Male | 9 | 11.9 | 75.5 | (34.5-143.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 35 | 28.8 | 121.5 | (84.6-169) | Female | 7 | 9.3 | 75.3 | (30.1-155.1) |
| Female | 26 | 28.2 | 92.2 | (60.2-135.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 8.1 | 86.8 | (34.8-178.8) |
| Male | 6 | 6.8 | 87.7 | (32-190.9) | Female | 10 | 8.3 | 120.8 | (57.8-222.2) |
| Female | 1 | 1.7 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 106 | 97 | 109.3 | (89.5-132.2) |
| Male | 3 | 2.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 2 | nc | (nc-nc) | Male | 2 | 5.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 3.4 | nc | (nc-nc) |
| Male | 11 | 14.5 | 76 | (37.9-136) | <u>Testis</u> | | | | |
| Female | 7 | 8 | 87.3 | (35-179.8) | Male | 6 | 4.4 | 137.9 | (50.4-300.2) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 9 | 3.8 | 236.5 | (107.9-449) | Male | 4 | 7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 24 | 22.5 | 106.6 | (68.3-158.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 10 | 109.8 | (54.7-196.4) | Female | 25 | 23.6 | 106.1 | (68.7-156.7) |
| Female | 4 | 7.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 359 | 345.5 | 103.9 | (93.4-115.2) |
| Male | 9 | 8.4 | 107.8 | (49.2-204.6) | Female | 326 | 347.2 | 93.9 | (84-104.7) |
| Female | 0 | 2.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 50 | 44.3 | 113 | (83.8-148.9) | | | | | |
| Female | 44 | 45.2 | 97.3 | (70.7-130.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 5.1 | nc | (nc-nc) | Male | 5 | 3.4 | 146.5 | (47.2-342) |
| Female | 1 | 1.8 | nc | (nc-nc) | Female | 3 | 2.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 3 | 3 | nc | (nc-nc) |
| Female | 18 | 19.5 | 92.2 | (54.6-145.7) | Female | 1 | 2.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 2.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 9 | 5.9 | 151.9 | (69.3-288.4) | Female | 4 | 1.8 | nc | (nc-nc) |
| Female | 3 | 5.6 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 1.7 | nc | (nc-nc) |
| Male | 0 | 1.4 | nc | (nc-nc) | Female | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 21 | 19.6 | 107.1 | (66.3-163.7) |
| Male | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.3 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.7 | nc | (nc-nc) |
| Male | 3 | 2.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 1.5 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 3 | 3.7 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 2 | nc | (nc-nc) | Female | 5 | 4.4 | 112.6 | (36.3-262.7) |
| Female | 0 | 1.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 64 | 70.2 | 91.1 | (70.2-116.4) |
| Male | 1 | 1.7 | nc | (nc-nc) | Female | 50 | 66.3 | 75.4 | (56-99.4) |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 5 | 9.4 | 53.3 | (17.2-124.3) | | | | | |
| Female | 5 | 9.3 | 53.8 | (17.4-125.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 14 | 14.2 | 98.4 | (53.7-165.1) | Male | 21 | 9.9 | 211.2 | (130.7-322.8) |
| Female | 9 | 4.8 | 186.6 | (85.2-354.3) | Female | 12 | 7.7 | 155.9 | (80.5-272.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 3.1 | 194.2 | (70.9-422.8) | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) | Female | 0 | 2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 12 | 8.7 | 138.4 | (71.4-241.8) |
| Female | 73 | 58.5 | 124.7 | (97.8-156.8) | Female | 6 | 6.6 | 90.4 | (33-196.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 2.2 | nc | (nc-nc) | Male | 3 | 7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 21 | 16.9 | 124.1 | (76.8-189.7) | Female | 4 | 5.1 | nc | (nc-nc) |
| Female | 16 | 15.4 | 103.6 | (59.2-168.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 4.8 | nc | (nc-nc) |
| Male | 6 | 4.1 | 145.9 | (53.3-317.5) | Female | 4 | 4.6 | nc | (nc-nc) |
| Female | 0 | 1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 47 | 59 | 79.7 | (58.6-106) |
| Male | 2 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 1 | nc | (nc-nc) | Male | 1 | 3.5 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 1.9 | nc | (nc-nc) |
| Male | 4 | 8.5 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 2 | 4.5 | nc | (nc-nc) | Male | 0 | 2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 2.3 | nc | (nc-nc) | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) | Female | 15 | 11.6 | 129.8 | (72.6-214.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 5.8 | 139 | (59.8-273.8) | Female | 12 | 13.4 | 89.7 | (46.3-156.8) |
| Female | 4 | 4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 195 | 204.7 | 95.2 | (82.3-109.6) |
| Male | 2 | 5 | nc | (nc-nc) | Female | 197 | 191.6 | 102.8 | (88.9-118.2) |
| Female | 2 | 1.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 18 | 26.8 | 67.2 | (39.8-106.2) | | | | | |
| Female | 14 | 25.8 | 54.2 | (29.6-91) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 25 | 30.5 | 82 | (53.1-121.1) | Male | 11 | 19.8 | 55.5 | (27.7-99.4) |
| Female | 6 | 12 | 49.8 | (18.2-108.5) | Female | 13 | 17.6 | 73.9 | (39.3-126.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 5.7 | 104.9 | (38.3-228.4) | Male | 1 | 5.5 | nc | (nc-nc) |
| Female | 7 | 5.3 | 132.5 | (53.1-272.9) | Female | 8 | 4.8 | 166.9 | (71.8-328.8) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1 | nc | (nc-nc) | Male | 18 | 17.4 | 103.3 | (61.2-163.3) |
| Female | 142 | 123.2 | 115.3 | (97.1-135.9) | Female | 11 | 15.7 | 70.3 | (35-125.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 5 | 4.5 | 111.4 | (35.9-260.1) | Male | 10 | 13.3 | 75.4 | (36.1-138.6) |
| Female | | | | | Female | 9 | 6.2 | 145.4 | (66.3-276) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 33 | 34.7 | 95.1 | (65.4-133.5) | Female | 17 | 11.5 | 147.6 | (85.9-236.4) |
| Female | 32 | 38.7 | 82.6 | (56.5-116.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 10 | 10 | 99.7 | (47.7-183.4) |
| Male | 9 | 8.2 | 109.4 | (49.9-207.7) | Female | 13 | 11.7 | 111 | (59-189.8) |
| Female | 4 | 2.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 92 | 114.2 | 80.6 | (65-98.8) |
| Male | 4 | 2.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 2.7 | nc | (nc-nc) | Male | 2 | 7.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 4.8 | nc | (nc-nc) |
| Male | 14 | 16.1 | 86.8 | (47.4-145.7) | <u>Testis</u> | | | | |
| Female | 12 | 9.9 | 121.5 | (62.7-212.3) | Male | 2 | 4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 4.5 | nc | (nc-nc) | Male | 5 | 7.2 | 69.8 | (22.5-162.8) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 13 | 24.4 | 53.2 | (28.3-90.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 11.7 | 68.5 | (29.5-135) | Female | 28 | 28.1 | 99.8 | (66.3-144.2) |
| Female | 10 | 9.5 | 104.7 | (50.1-192.6) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 323 | 409.3 | 78.9 | (70.5-88) |
| Male | 10 | 9.7 | 103.6 | (49.6-190.5) | Female | 414 | 432.4 | 95.7 | (86.7-105.4) |
| Female | 0 | 3.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 36 | 55.1 | 65.4 | (45.8-90.5) | | | | | |
| Female | 50 | 59.3 | 84.3 | (62.5-111.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 18 | 13.3 | 135.4 | (80.2-213.9) | Male | 4 | 9.4 | nc | (nc-nc) |
| Female | 7 | 4.8 | 144.8 | (58-298.3) | Female | 10 | 7.7 | 130.1 | (62.3-239.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 3 | nc | (nc-nc) | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) | Female | 2 | 2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 5 | 8.3 | 60.5 | (19.5-141.3) |
| Female | 57 | 58.1 | 98 | (74.2-127) | Female | 3 | 6.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 2.2 | nc | (nc-nc) | Male | 2 | 6.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 16.1 | 93.4 | (52.3-154.1) | Female | 4 | 5.1 | nc | (nc-nc) |
| Female | 19 | 15.6 | 121.5 | (73.1-189.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 4.5 | 199.2 | (90.9-378.2) |
| Male | 4 | 3.9 | nc | (nc-nc) | Female | 5 | 4.6 | 108.1 | (34.8-252.2) |
| Female | 0 | 1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 54 | 55.4 | 97.4 | (73.2-127.1) |
| Male | 2 | 1.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1 | nc | (nc-nc) | Male | 3 | 3.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 1.9 | nc | (nc-nc) |
| Male | 6 | 8.1 | 73.9 | (27-160.9) | <u>Testis</u> | | | | |
| Female | 3 | 4.4 | nc | (nc-nc) | Male | 0 | 2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.2 | nc | (nc-nc) | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 6 | 11.6 | 51.9 | (19-113.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 5.5 | 200.8 | (100.1-359.3) | Female | 12 | 13.1 | 91.6 | (47.3-160) |
| Female | 4 | 4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 177 | 193.4 | 91.5 | (78.5-106) |
| Male | 2 | 4.8 | nc | (nc-nc) | Female | 175 | 190.9 | 91.7 | (78.6-106.3) |
| Female | 0 | 1.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 19 | 25 | 75.9 | (45.7-118.5) | | | | | |
| Female | 18 | 25.4 | 70.7 | (41.9-111.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 23 | 15.1 | 152.7 | (96.8-229.2) | Male | 3 | 9.9 | nc | (nc-nc) |
| Female | 8 | 6.1 | 131.3 | (56.5-258.7) | Female | 5 | 8.5 | 58.9 | (19-137.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 3 | nc | (nc-nc) | Male | 7 | 2.7 | 258.4 | (103.5-532.5) |
| Female | 2 | 2.7 | nc | (nc-nc) | Female | 5 | 2.4 | 207.9 | (67-485.2) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 5 | 8.8 | 56.8 | (18.3-132.5) |
| Female | 57 | 61.4 | 92.9 | (70.4-120.4) | Female | 8 | 7.8 | 102.3 | (44-201.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 2.3 | nc | (nc-nc) | Male | 9 | 6.6 | 136.8 | (62.4-259.7) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 18 | 17.4 | 103.5 | (61.3-163.6) | Female | 7 | 5.6 | 124.1 | (49.7-255.7) |
| Female | 27 | 19.7 | 137.1 | (90.4-199.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 4 | 5 | nc | (nc-nc) |
| Male | 7 | 4 | 175.5 | (70.3-361.5) | Female | 9 | 6 | 151.1 | (69-286.9) |
| Female | 0 | 1.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 63 | 54.3 | 115.9 | (89.1-148.3) |
| Male | 1 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | Male | 0 | 3.6 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 2.5 | nc | (nc-nc) |
| Male | 14 | 8.1 | 173.4 | (94.7-290.9) | <u>Testis</u> | | | | |
| Female | 3 | 4.9 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 2.2 | nc | (nc-nc) | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 12 | 11.6 | 103.3 | (53.3-180.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 9 | 6 | 149.2 | (68.1-283.3) | Female | 14 | 13.6 | 102.9 | (56.2-172.6) |
| Female | 1 | 4.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 225 | 201.6 | 111.6 | (97.5-127.2) |
| Male | 7 | 4.7 | 148.6 | (59.5-306.2) | Female | 212 | 215.2 | 98.5 | (85.7-112.7) |
| Female | 3 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 27 | 26.9 | 100.6 | (66.2-146.3) | | | | | |
| Female | 26 | 29.6 | 87.7 | (57.3-128.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 3.8 | nc | (nc-nc) | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) | Female | 3 | 1.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 15 | 14.1 | 106.6 | (59.6-175.9) | Female | 0 | 1.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 1.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 4.4 | 113.6 | (36.6-265.1) | Female | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 4 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 12 | 15 | 79.8 | (41.2-139.5) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 1.5 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1 | nc | (nc-nc) | Female | 2 | 2.6 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Female | 4 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 4 | 7 | nc | (nc-nc) | Male | 37 | 52.4 | 70.6 | (49.7-97.3) |
| Female | 3 | 6.5 | nc | (nc-nc) | Female | 41 | 47.2 | 86.8 | (62.3-117.8) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 8 | 14.6 | 54.9 | (23.6-108.2) | Male | 12 | 10.7 | 112.5 | (58.1-196.6) |
| Female | 6 | 5.4 | 110.3 | (40.3-240.2) | Female | 14 | 9.3 | 151.3 | (82.7-253.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 3.5 | 142.4 | (45.9-332.3) | Male | 5 | 2.8 | 177.7 | (57.3-414.7) |
| Female | 4 | 2.9 | nc | (nc-nc) | Female | 3 | 2.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 7 | 9.4 | 74.7 | (29.9-153.9) |
| Female | 68 | 66.6 | 102.2 | (79.3-129.5) | Female | 9 | 7.6 | 117.8 | (53.7-223.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 2.7 | nc | (nc-nc) | Male | 8 | 7.6 | 105.6 | (45.5-208.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 23 | 17.9 | 128.5 | (81.4-192.9) | Female | 8 | 5.9 | 134.9 | (58.1-265.8) |
| Female | 29 | 17.7 | 163.9 | (109.8-235.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 5 | 140.4 | (56.3-289.3) |
| Male | 7 | 4.3 | 163.3 | (65.4-336.5) | Female | 5 | 5.2 | 96.2 | (31-224.6) |
| Female | 3 | 1.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 65 | 61.5 | 105.6 | (81.5-134.6) |
| Male | 2 | 1.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.4 | nc | (nc-nc) | Male | 4 | 3.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 2.1 | nc | (nc-nc) |
| Male | 12 | 9.1 | 131.3 | (67.8-229.3) | <u>Testis</u> | | | | |
| Female | 6 | 5.1 | 118.4 | (43.2-257.7) | Male | 4 | 2.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.4 | nc | (nc-nc) | Male | 8 | 4.5 | 178.5 | (76.8-351.7) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 15 | 14.5 | 103.7 | (58-171.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 6.3 | 79.7 | (25.7-186) | Female | 20 | 15 | 133.3 | (81.4-205.9) |
| Female | 7 | 4.8 | 146.4 | (58.7-301.7) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 239 | 216.5 | 110.4 | (96.8-125.3) |
| Male | 9 | 5.3 | 170.6 | (77.8-323.8) | Female | 243 | 219.9 | 110.5 | (97-125.3) |
| Female | 0 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 29 | 27.3 | 106 | (71-152.3) | | | | | |
| Female | 27 | 28.4 | 95.2 | (62.7-138.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 13 | 12.1 | 107.2 | (57-183.4) | Male | 10 | 8 | 124.7 | (59.7-229.4) |
| Female | 0 | 4.4 | nc | (nc-nc) | Female | 11 | 6.2 | 177.4 | (88.4-317.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.4 | nc | (nc-nc) | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | Female | 4 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 4 | 7 | nc | (nc-nc) |
| Female | 39 | 47.7 | 81.7 | (58.1-111.7) | Female | 8 | 5.8 | 138.9 | (59.8-273.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | Male | 5 | 5.6 | 89.1 | (28.7-207.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 14 | 106.9 | (59.8-176.2) | Female | 8 | 4.3 | 185.9 | (80-366.3) |
| Female | 11 | 14.1 | 78.1 | (38.9-139.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 4.1 | nc | (nc-nc) |
| Male | 1 | 3.4 | nc | (nc-nc) | Female | 6 | 4.3 | 140.6 | (51.3-305.9) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 51 | 48.8 | 104.6 | (77.9-137.5) |
| Male | 1 | 0.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 0.7 | nc | (nc-nc) | Male | 2 | 2.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 1.7 | nc | (nc-nc) |
| Male | 5 | 6.8 | 73.8 | (23.8-172.2) | <u>Testis</u> | | | | |
| Female | 3 | 3.8 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 6 | 8.4 | 71.2 | (26-155) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 4.7 | 105.7 | (34.1-246.7) | Female | 12 | 11 | 109.4 | (56.5-191.1) |
| Female | 5 | 3.5 | 143.8 | (46.3-335.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 152 | 168.3 | 90.3 | (76.5-105.9) |
| Male | 1 | 4 | nc | (nc-nc) | Female | 156 | 161.4 | 96.6 | (82.1-113) |
| Female | 1 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 17 | 22.5 | 75.6 | (44-121.1) | | | | | |
| Female | 17 | 22.4 | 75.9 | (44.2-121.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 24 | 35.7 | 67.3 | (43.1-100.1) | Male | 31 | 22.2 | 139.6 | (94.8-198.1) |
| Female | 13 | 14 | 92.9 | (49.4-158.9) | Female | 25 | 18.3 | 136.8 | (88.5-201.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 11 | 6.3 | 173.5 | (86.5-310.5) | Male | 6 | 6.2 | 96.3 | (35.2-209.7) |
| Female | 9 | 5.6 | 159.7 | (72.9-303.2) | Female | 6 | 5.5 | 108.7 | (39.7-236.6) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1.1 | nc | (nc-nc) | Male | 26 | 19.7 | 132.2 | (86.4-193.8) |
| Female | 147 | 133.6 | 110 | (93-129.3) | Female | 15 | 17.5 | 85.5 | (47.8-141.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 5 | 4.6 | 108.3 | (34.9-252.7) | Male | 15 | 14 | 106.8 | (59.7-176.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 46 | 39.2 | 117.5 | (86-156.7) | Female | 15 | 12.4 | 121 | (67.7-199.6) |
| Female | 48 | 44 | 109.1 | (80.5-144.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 16 | 11.5 | 139.2 | (79.5-226) |
| Male | 12 | 9.1 | 131.6 | (67.9-230) | Female | 16 | 13.7 | 117.2 | (66.9-190.3) |
| Female | 3 | 2.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 94 | 123.2 | 76.3 | (61.6-93.4) |
| Male | 4 | 2.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 2.2 | nc | (nc-nc) | Male | 12 | 8.2 | 145.5 | (75.1-254.1) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 6 | 5.5 | 109.7 | (40-238.7) |
| Male | 19 | 17.6 | 107.7 | (64.8-168.2) | <u>Testis</u> | | | | |
| Female | 14 | 11.1 | 126.4 | (69-212) | Male | 9 | 4.3 | 211.7 | (96.6-401.9) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 9 | 4.9 | 182.4 | (83.2-346.3) | Male | 10 | 7.6 | 131.9 | (63.2-242.6) |
| Female | 2 | 1.6 | nc | (nc-nc) | Female | 30 | 23.6 | 127.1 | (85.7-181.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 13.4 | 82 | (40.9-146.7) | Female | 35 | 30.3 | 115.6 | (80.5-160.8) |
| Female | 7 | 10.6 | 66 | (26.4-136) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 490 | 456.7 | 107.3 | (98-117.2) |
| Male | 15 | 10.3 | 145.1 | (81.2-239.3) | Female | 525 | 477.2 | 110 | (100.8-119.8) |
| Female | 2 | 3.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 71 | 63.5 | 111.8 | (87.3-141) | | | | | |
| Female | 84 | 69.9 | 120.2 | (95.9-148.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 4.9 | 101.2 | (32.6-236.2) | Male | 7 | 3.3 | 215 | (86.1-443.1) |
| Female | 0 | 2 | nc | (nc-nc) | Female | 1 | 2.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 19 | 19.8 | 95.8 | (57.6-149.6) | Female | 1 | 2.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 5.6 | 88.8 | (28.6-207.3) | Female | 1 | 1.8 | nc | (nc-nc) |
| Female | 5 | 6.2 | 80.4 | (25.9-187.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 1.6 | nc | (nc-nc) |
| Male | 1 | 1.3 | nc | (nc-nc) | Female | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 21 | 18.9 | 111.3 | (68.9-170.1) |
| Male | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.8 | nc | (nc-nc) |
| Male | 1 | 2.7 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 2 | 1.6 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 4 | 3.5 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.9 | nc | (nc-nc) | Female | 9 | 4.6 | 196.6 | (89.7-373.2) |
| Female | 1 | 1.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 61 | 67.1 | 90.9 | (69.5-116.8) |
| Male | 3 | 1.6 | nc | (nc-nc) | Female | 66 | 69.4 | 95.1 | (73.6-121) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 5 | 9.1 | 55 | (17.7-128.4) | | | | | |
| Female | 11 | 10.1 | 109.2 | (54.4-195.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 1.8 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 6 | 7.1 | 84.1 | (30.7-183) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 2.2 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 10 | 7.6 | 131.3 | (62.8-241.4) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Female | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 27 | 26.4 | 102.2 | (67.3-148.7) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 16 | 22.3 | 71.9 | (41.1-116.8) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 3 | 3.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 2.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 11 | 8.7 | 127.1 | (63.4-227.5) | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) | Female | 2 | 4.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 1.7 | nc | (nc-nc) | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) | Female | 0 | 1.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 7 | 5 | 140 | (56.1-288.5) |
| Female | 37 | 33.6 | 110 | (77.4-151.6) | Female | 3 | 4.1 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.2 | nc | (nc-nc) | Male | 3 | 3.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 12 | 9.8 | 122.1 | (63-213.2) | Female | 1 | 3.1 | nc | (nc-nc) |
| Female | 5 | 9.9 | 50.7 | (16.3-118.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 3 | 2.4 | nc | (nc-nc) | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 3 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 34 | 34 | 100 | (69.3-139.8) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 7 | 4.7 | 147.4 | (59.1-303.7) | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 3.4 | nc | (nc-nc) | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) | Female | 7 | 6.3 | 111.4 | (44.6-229.6) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 2.8 | nc | (nc-nc) | Female | 15 | 7.8 | 192.3 | (107.5-317.2) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 17 | 16 | 106 | (61.7-169.8) | Male | 117 | 118.9 | 98.4 | (81.4-117.9) |
| Female | 14 | 16.4 | 85.6 | (46.8-143.6) | Female | 104 | 115.2 | 90.2 | (73.7-109.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|---|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 15 | 16.7 | 89.6 | (50.1-147.8) | Male | 18 | 9.1 | 198 | (117.3-312.9) |
| Female | 6 | 5.6 | 106.2 | (38.8-231.2) | Female | 11 | 5.9 | 186 | (92.7-332.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 1 | 2.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 7 | 8 | 87.2 | (34.9-179.7) |
| Female | 68 | 46 | 147.8 | (114.8-187.4) | Female | 5 | 6.6 | 75.8 | (24.4-176.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Male | 2 | 5.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 16 | 16.9 | 94.7 | (54.1-153.8) | Female | 4 | 4.4 | nc | (nc-nc) |
| Female | 18 | 16.9 | 106.2 | (62.9-167.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 5.2 | nc | (nc-nc) |
| Male | 3 | 4 | nc | (nc-nc) | Female | 4 | 5.5 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 58 | 52.6 | 110.2 | (83.6-142.4) |
| Male | 0 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 3.6 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 2.1 | nc | (nc-nc) |
| Male | 3 | 6.9 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 4.1 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.1 | nc | (nc-nc) | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 4 | 5.8 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 5.5 | 126.4 | (50.6-260.5) | Female | 19 | 10.9 | 174.2 | (104.8-272) |
| Female | 3 | 3.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 171 | 194.2 | 88.1 | (75.4-102.3) |
| Male | 2 | 4.1 | nc | (nc-nc) | Female | 189 | 172.6 | 109.5 | (94.4-126.3) |
| Female | 1 | 1.5 | nc | (nc-nc) | <u>Lung and Bronchus</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | <u>Bladder, Urinary</u> | | | | |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Male | 15 | 16.7 | 89.6 | (50.1-147.8) |
| <u>Lung and Bronchus</u> | | | | | Female | 6 | 5.6 | 106.2 | (38.8-231.2) |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | <u>Brain and Other Nervous System</u> | | | | |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Male | 1 | 2.1 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | Female | 2 | 1.8 | nc | (nc-nc) |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | <u>Breast</u> | | | | |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Male | 0 | 0.5 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | Female | 68 | 46 | 147.8 | (114.8-187.4) |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | <u>Cervix Uteri</u> | | | | |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Colon / Rectum</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 16 | 16.9 | 94.7 | (54.1-153.8) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 18 | 16.9 | 106.2 | (62.9-167.9) |
| <u>Lung and Bronchus</u> | | | | | <u>Esophagus</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 3 | 4 | nc | (nc-nc) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 1 | 1.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Hodgkin Lymphoma</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Kidney & Renal Pelvis</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 3 | 6.9 | nc | (nc-nc) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 1 | 4.1 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Larynx</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 7 | 5.5 | 126.4 | (50.6-260.5) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 3 | 3.8 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Liver and Intrahepatic Bile Ducts</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 1 | 1.5 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 11 | 29.4 | 37.5 | (18.7-67) | Male | 11 | 29.4 | 37.5 | (18.7-67) |
| Female | 19 | 28.3 | 67 | (40.3-104.7) | Female | 19 | 28.3 | 67 | (40.3-104.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 2.3 | nc | (nc-nc) | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 2 | 0.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 10 | 7.2 | 138.1 | (66.1-254) | Female | 2 | 0.8 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2.6 | nc | (nc-nc) | Female | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 12 | 9.2 | 130.8 | (67.5-228.5) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.2 | nc | (nc-nc) |
| Male | 1 | 1.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Female | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 28 | 31.4 | 89.3 | (59.3-129) |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 25 | 23.8 | 105.1 | (68-155.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 5 | 4.3 | 116.4 | (37.5-271.7) | | | | | |
| Female | 5 | 3.4 | 147.3 | (47.5-343.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 18 | 12.8 | 140.3 | (83.1-221.7) | Male | 7 | 8.9 | 78.3 | (31.4-161.4) |
| Female | 8 | 4.5 | 177 | (76.2-348.7) | Female | 9 | 7.3 | 122.7 | (56-232.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 2.8 | nc | (nc-nc) | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) | Female | 2 | 1.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 9 | 7.8 | 114.8 | (52.4-217.9) |
| Female | 49 | 54.3 | 90.2 | (66.7-119.2) | Female | 7 | 6.2 | 112.1 | (44.9-231) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 2.1 | nc | (nc-nc) | Male | 8 | 6.2 | 128.7 | (55.4-253.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 15.3 | 52.4 | (22.5-103.2) | Female | 5 | 4.8 | 103.9 | (33.5-242.5) |
| Female | 16 | 14.5 | 110 | (62.8-178.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 4.3 | nc | (nc-nc) |
| Male | 3 | 3.7 | nc | (nc-nc) | Female | 4 | 4.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 46 | 51.9 | 88.6 | (64.9-118.2) |
| Male | 0 | 1.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1 | nc | (nc-nc) | Male | 2 | 3.2 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 1.7 | nc | (nc-nc) |
| Male | 5 | 7.6 | 66.2 | (21.3-154.5) | <u>Testis</u> | | | | |
| Female | 6 | 4.2 | 143.1 | (52.2-311.4) | Male | 4 | 2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2 | nc | (nc-nc) | Male | 7 | 3.5 | 198.7 | (79.6-409.4) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 6 | 11.1 | 54 | (19.7-117.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 5.2 | 133.4 | (53.5-274.9) | Female | 21 | 12.4 | 170 | (105.2-259.9) |
| Female | 5 | 3.8 | 132.6 | (42.7-309.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 185 | 183.1 | 101.1 | (87-116.7) |
| Male | 4 | 4.4 | nc | (nc-nc) | Female | 194 | 179.7 | 108 | (93.3-124.3) |
| Female | 0 | 1.4 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 38 | 23.8 | 159.5 | (112.8-218.9) | | | | | |
| Female | 30 | 24.3 | 123.6 | (83.4-176.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 19 | 14 | 136.1 | (81.9-212.5) | Male | 12 | 9.1 | 131.2 | (67.7-229.3) |
| Female | 9 | 5.5 | 164.9 | (75.2-313) | Female | 10 | 7.4 | 134.3 | (64.3-247.1) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 2.7 | nc | (nc-nc) | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) | Female | 1 | 2.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 3 | 8.1 | nc | (nc-nc) |
| Female | 48 | 54.8 | 87.6 | (64.6-116.1) | Female | 7 | 7 | 100.4 | (40.2-206.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.9 | nc | (nc-nc) | Male | 5 | 6.1 | 81.9 | (26.4-191) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 10 | 16 | 62.5 | (29.9-115) | Female | 3 | 5 | nc | (nc-nc) |
| Female | 14 | 17.4 | 80.5 | (44-135.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 4.6 | 108.8 | (35.1-254) |
| Male | 4 | 3.8 | nc | (nc-nc) | Female | 7 | 5.3 | 131.7 | (52.8-271.4) |
| Female | 1 | 1.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 38 | 51.9 | 73.2 | (51.8-100.5) |
| Male | 2 | 1.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.9 | nc | (nc-nc) | Male | 3 | 3.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 2.2 | nc | (nc-nc) |
| Male | 7 | 7.5 | 93.3 | (37.4-192.3) | <u>Testis</u> | | | | |
| Female | 2 | 4.4 | nc | (nc-nc) | Male | 1 | 1.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 2.1 | nc | (nc-nc) | Male | 5 | 3.4 | 149 | (48-347.8) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 8 | 10 | 80.2 | (34.5-158) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 5.4 | 91.9 | (29.6-214.4) | Female | 13 | 12.3 | 105.6 | (56.2-180.6) |
| Female | 6 | 4.2 | 142.4 | (52-310) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 172 | 188 | 91.5 | (78.3-106.2) |
| Male | 4 | 4.4 | nc | (nc-nc) | Female | 168 | 191.9 | 87.6 | (74.8-101.8) |
| Female | 3 | 1.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 30 | 25.3 | 118.4 | (79.9-169.1) | | | | | |
| Female | 22 | 27.3 | 80.6 | (50.5-122) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 5.6 | 107.8 | (39.3-234.6) | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) | Female | 0 | 2.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1 | nc | (nc-nc) | Male | 1 | 1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 24 | 18.6 | 129 | (82.6-192) | Female | 0 | 2.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 2 | 2.4 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 6.2 | nc | (nc-nc) | Female | 3 | 1.7 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 1.8 | nc | (nc-nc) |
| Male | 1 | 1.5 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 19 | 20.6 | 92.3 | (55.5-144.1) |
| Male | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 1.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 0.6 | nc | (nc-nc) |
| Male | 0 | 2.9 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 1.5 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 0.8 | nc | (nc-nc) | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 2 | 3.5 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | Female | 5 | 4.3 | 116.9 | (37.7-272.8) |
| Female | 2 | 1.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 60 | 73.9 | 81.2 | (61.9-104.5) |
| Male | 1 | 1.7 | nc | (nc-nc) | Female | 56 | 62.6 | 89.5 | (67.6-116.2) |
| Female | 2 | 0.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 6 | 10.1 | 59.2 | (21.6-128.9) | | | | | |
| Female | 4 | 8.8 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 76 | 70.1 | 108.4 | (85.4-135.7) | Male | 36 | 43.2 | 83.2 | (58.3-115.3) |
| Female | 35 | 27 | 129.9 | (90.4-180.6) | Female | 36 | 34.3 | 105 | (73.5-145.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 12 | 12 | 99.8 | (51.5-174.3) | Male | 12 | 12.3 | 97.9 | (50.5-171) |
| Female | 9 | 10.6 | 85.3 | (38.9-161.9) | Female | 19 | 10.7 | 178.4 | (107.3-278.5) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 4 | 2.2 | nc | (nc-nc) | Male | 49 | 38.2 | 128.4 | (95-169.7) |
| Female | 242 | 256 | 94.5 | (83-107.2) | Female | 51 | 33.6 | 151.9 | (113.1-199.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 12 | 8.5 | 142 | (73.3-248.1) | Male | 35 | 27.7 | 126.5 | (88.1-175.9) |
| Female | | | | | Female | 14 | 13 | 107.8 | (58.9-180.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 74 | 76.8 | 96.3 | (75.6-121) | Female | 22 | 23.7 | 92.7 | (58.1-140.3) |
| Female | 91 | 84.3 | 107.9 | (86.9-132.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 19 | 22.6 | 83.9 | (50.5-131) |
| Male | 12 | 18 | 66.5 | (34.3-116.2) | Female | 34 | 26.3 | 129.5 | (89.6-180.9) |
| Female | 5 | 5.5 | 91.3 | (29.4-213) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 276 | 245.8 | 112.3 | (99.4-126.3) |
| Male | 3 | 4.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 5 | 3.9 | 127.6 | (41.1-297.8) | Male | 16 | 16.2 | 98.7 | (56.4-160.4) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 10 | 10.5 | 95.6 | (45.7-175.7) |
| Male | 40 | 34.6 | 115.7 | (82.7-157.6) | <u>Testis</u> | | | | |
| Female | 22 | 21.3 | 103.5 | (64.8-156.7) | Male | 12 | 7.1 | 169.8 | (87.6-296.6) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 13 | 9.8 | 133 | (70.7-227.4) | Male | 13 | 14.4 | 90.3 | (48-154.4) |
| Female | 2 | 3.1 | nc | (nc-nc) | Female | 38 | 42.9 | 88.5 | (62.6-121.5) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 33 | 25.9 | 127.4 | (87.7-178.9) | Female | 66 | 58.5 | 112.7 | (87.2-143.4) |
| Female | 29 | 20 | 145 | (97.1-208.2) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 989 | 897.4 | 110.2 | (103.4-117.3) |
| Male | 26 | 20.4 | 127.2 | (83.1-186.3) | Female | 1002 | 912.3 | 109.8 | (103.1-116.9) |
| Female | 8 | 7.6 | 105 | (45.2-206.8) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 134 | 125.4 | 106.9 | (89.5-126.6) | | | | | |
| Female | 170 | 135.3 | 125.6 | (107.5-146) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 5 | 6.6 | 75.9 | (24.5-177.2) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 4 | 1.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.6 | nc | (nc-nc) |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 8 | 7.6 | 105.7 | (45.5-208.3) |
| Male | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.2 | nc | (nc-nc) |
| Male | 1 | 1 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 17 | 26 | 65.4 | (38.1-104.7) |
| Male | 0 | 0.6 | nc | (nc-nc) | Female | 15 | 21.3 | 70.4 | (39.4-116.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 0 | 3.6 | nc | (nc-nc) | | | | | |
| Female | 1 | 2.9 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 20 | 15.6 | 127.9 | (78.1-197.5) | Male | 16 | 11.3 | 141 | (80.5-229) |
| Female | 4 | 5.3 | nc | (nc-nc) | Female | 12 | 9.2 | 131 | (67.6-228.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 3.6 | nc | (nc-nc) | Male | 2 | 3 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) | Female | 0 | 2.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 12 | 9.9 | 121.7 | (62.8-212.7) |
| Female | 87 | 69.1 | 125.8 | (100.8-155.2) | Female | 7 | 7.6 | 92 | (36.8-189.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 2.7 | nc | (nc-nc) | Male | 7 | 8.2 | 85.7 | (34.4-176.7) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 22 | 19 | 115.7 | (72.5-175.2) | Female | 6 | 6 | 99.3 | (36.3-216.2) |
| Female | 18 | 17.1 | 105.3 | (62.4-166.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 3 | 4.7 | nc | (nc-nc) | Male | 75 | 68.5 | 109.5 | (86.1-137.2) |
| Female | 2 | 1.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.6 | nc | (nc-nc) | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 9 | 9.8 | 91.5 | (41.8-173.7) | Female | 17 | 16 | 106.2 | (61.8-170.1) |
| Female | 6 | 5.2 | 115 | (42-250.3) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 2.6 | nc | (nc-nc) | Male | 249 | 233.7 | 106.5 | (93.7-120.6) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 264 | 222.7 | 118.5 | (104.7-133.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 10 | 6.6 | 152.4 | (72.9-280.2) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Female | 3 | 4.6 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 5.7 | 121.9 | (48.9-251.3) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Female | 0 | 1.7 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 34 | 29.9 | 113.9 | (78.8-159.1) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Female | 44 | 29.3 | 150.1 | (109.1-201.5) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 8 | 9.1 | 88.1 | (37.9-173.6) | Male | 6 | 6.8 | 88.6 | (32.3-192.8) |
| Female | 1 | 3.2 | nc | (nc-nc) | Female | 2 | 5.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 2.3 | nc | (nc-nc) | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) | Female | 2 | 1.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 8 | 5.9 | 134.6 | (58-265.2) |
| Female | 50 | 42.2 | 118.4 | (87.9-156.1) | Female | 5 | 4.6 | 108.9 | (35.1-254.2) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 1.7 | nc | (nc-nc) | Male | 3 | 5 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 11.4 | 70.2 | (30.2-138.2) | Female | 1 | 3.7 | nc | (nc-nc) |
| Female | 13 | 10.5 | 124 | (66-212) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 3.1 | nc | (nc-nc) |
| Male | 4 | 2.7 | nc | (nc-nc) | Female | 7 | 3 | 230.7 | (92.4-475.4) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 36 | 39.6 | 90.8 | (63.6-125.8) |
| Male | 1 | 1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.8 | nc | (nc-nc) | Male | 6 | 2.3 | 258.3 | (94.3-562.2) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 1.2 | nc | (nc-nc) |
| Male | 6 | 5.9 | 101.2 | (36.9-220.2) | <u>Testis</u> | | | | |
| Female | 5 | 3.1 | 159.2 | (51.3-371.5) | Male | 0 | 1.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 1.5 | nc | (nc-nc) | Male | 5 | 2.9 | 173.3 | (55.8-404.4) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 3 | 8.9 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 3.9 | 127.1 | (41-296.6) | Female | 10 | 9.6 | 104.7 | (50.1-192.5) |
| Female | 4 | 2.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 133 | 137.9 | 96.5 | (80.8-114.3) |
| Male | 1 | 3.5 | nc | (nc-nc) | Female | 140 | 135.1 | 103.6 | (87.2-122.3) |
| Female | 0 | 1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 17 | 17.3 | 98.5 | (57.3-157.6) | | | | | |
| Female | 19 | 17.3 | 109.8 | (66.1-171.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|--------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 3 | 3 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Male</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Obs | 6 | 13.2 | 45.4 | (16.6-98.9) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Female</u> | | | | |
| <u>Leukemia</u> | | | | | Obs | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | 6 | 13.2 | 45.4 | (16.6-98.9) | |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Female</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Obs | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | 5 | 9.3 | 53.7 | (17.3-125.3) | |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Female</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Obs | | | | |
| Male | 1 | 1.7 | nc | (nc-nc) | 6 | 13.2 | 45.4 | (16.6-98.9) | |
| Female | 0 | 1.1 | nc | (nc-nc) | <u>Female</u> | | | | |
| | | | | | Obs | | | | |
| | | | | | 5 | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 1.7 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1 | nc | (nc-nc) |
| Female | 6 | 6.2 | 96.1 | (35.1-209.2) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Female | 5 | 7 | 71.3 | (23-166.3) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 1 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 4 | 3.3 | nc | (nc-nc) | Female | 14 | 24 | 58.4 | (31.9-98.1) |
| Female | 0 | 3.1 | nc | (nc-nc) | Female | 16 | 21.2 | 75.3 | (43-122.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1 | nc | (nc-nc) |
| Female | 6 | 6.1 | 98.6 | (36-214.6) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 0.3 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 6 | 6.8 | 88.2 | (32.2-192) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1 | nc | (nc-nc) | Female | 5 | 1.4 | 369.6 | (119.1-862.6) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Female</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 13 | 23.7 | 54.9 | (29.2-93.8) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 20 | 19 | 105.2 | (64.2-162.5) |
| <u>Leukemia</u> | | | | | <u>Male</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>Female</u> | | | | |
| Female | 1 | 0.4 | nc | (nc-nc) | <u>Male</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Female</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | <u>Male</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Female</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>Male</u> | | | | |
| Male | 1 | 3 | nc | (nc-nc) | <u>Female</u> | | | | |
| Female | 4 | 2.3 | nc | (nc-nc) | <u>Male</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 60 | 58.3 | 102.9 | (78.6-132.5) | Male | 29 | 36 | 80.6 | (54-115.8) |
| Female | 24 | 22.3 | 107.6 | (68.9-160.1) | Female | 37 | 28.6 | 129.4 | (91.1-178.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 15 | 10.1 | 147.9 | (82.7-244) | Male | 10 | 10.2 | 98.4 | (47.1-180.9) |
| Female | 6 | 8.9 | 67.6 | (24.7-147.2) | Female | 6 | 8.8 | 68 | (24.8-148.1) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 1.8 | nc | (nc-nc) | Male | 35 | 31.8 | 110 | (76.6-153) |
| Female | 207 | 211.6 | 97.8 | (85-112.1) | Female | 32 | 27.8 | 114.9 | (78.6-162.3) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 11 | 7 | 156.1 | (77.8-279.4) | Male | 27 | 22.9 | 118.1 | (77.8-171.8) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 73 | 63.7 | 114.6 | (89.8-144.1) | Female | 14 | 19.7 | 71.2 | (38.9-119.5) |
| Female | 94 | 69.6 | 135 | (109.1-165.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 19 | 18.8 | 101 | (60.8-157.8) |
| Male | 21 | 14.9 | 140.6 | (87-214.9) | Female | 18 | 21.7 | 82.8 | (49.1-130.9) |
| Female | 3 | 4.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 208 | 203 | 102.5 | (89-117.4) |
| Male | 4 | 4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 3.4 | nc | (nc-nc) | Male | 7 | 13.4 | 52.1 | (20.9-107.3) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 5 | 8.7 | 57.7 | (18.6-134.7) |
| Male | 30 | 28.6 | 104.7 | (70.7-149.5) | <u>Testis</u> | | | | |
| Female | 18 | 17.6 | 102.3 | (60.6-161.7) | Male | 7 | 6.3 | 111.8 | (44.8-230.3) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 9 | 8.1 | 111.2 | (50.7-211.1) | Male | 15 | 12 | 124.8 | (69.8-205.8) |
| Female | 3 | 2.6 | nc | (nc-nc) | Female | 30 | 36.1 | 83.1 | (56.1-118.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 25 | 21.7 | 115.2 | (74.5-170.1) | Female | 46 | 48.5 | 94.9 | (69.5-126.6) |
| Female | 8 | 16.7 | 47.9 | (20.6-94.3) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 780 | 745.2 | 104.7 | (97.5-112.3) |
| Male | 19 | 16.9 | 112.3 | (67.6-175.4) | Female | 780 | 755.8 | 103.2 | (96.1-110.7) |
| Female | 6 | 6.3 | 95.2 | (34.8-207.3) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 106 | 104.2 | 101.7 | (83.3-123) | | | | | |
| Female | 145 | 111.8 | 129.7 | (109.5-152.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 3 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Female | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 6 | 1.8 | 341.3 | (124.6-742.8) | Female | 17 | 12.9 | 131.5 | (76.6-210.5) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 5 | 9.6 | 52 | (16.8-121.4) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 11 | 8.2 | 134.6 | (67.1-240.9) | Male | 6 | 5.6 | 107.2 | (39.2-233.4) |
| Female | 3 | 3 | nc | (nc-nc) | Female | 3 | 4.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) | Female | 1 | 1.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 7 | 4.9 | 143.2 | (57.4-295) |
| Female | 33 | 33.7 | 98 | (67.4-137.6) | Female | 4 | 4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.2 | nc | (nc-nc) | Male | 5 | 3.8 | 131.2 | (42.3-306.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 9.5 | 52.9 | (17-123.3) | Female | 4 | 3 | nc | (nc-nc) |
| Female | 10 | 9.3 | 107.4 | (51.4-197.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 2.3 | nc | (nc-nc) | Female | 4 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 41 | 32.6 | 125.8 | (90.2-170.6) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 4 | 4.7 | nc | (nc-nc) | Female | 1 | 1.1 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 3 | 1.3 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 5 | 3.3 | 153.4 | (49.4-358) | Female | 7 | 6.5 | 107.2 | (43-221) |
| Female | 3 | 2.4 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 2 | 2.7 | nc | (nc-nc) | Male | 5 | 7.7 | 64.6 | (20.8-150.8) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 16 | 15.3 | 104.7 | (59.8-170.1) | Female | 117 | 113.2 | 103.4 | (85.5-123.9) |
| Female | 17 | 15.9 | 106.9 | (62.2-171.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 75 | 57.4 | 130.7 | (102.8-163.8) | Male | 58 | 38.9 | 149.1 | (113.2-192.8) |
| Female | 19 | 21.1 | 90.2 | (54.3-140.9) | Female | 61 | 31.2 | 195.7 | (149.7-251.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 8 | 11.8 | 67.6 | (29.1-133.1) | Male | 11 | 10.6 | 103.8 | (51.7-185.7) |
| Female | 11 | 9.6 | 114.6 | (57.1-205.1) | Female | 8 | 8.6 | 93.5 | (40.2-184.2) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1.8 | nc | (nc-nc) | Male | 35 | 34.1 | 102.7 | (71.5-142.8) |
| Female | 293 | 232.3 | 126.1 | (112.1-141.4) | Female | 39 | 28 | 139.5 | (99.2-190.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 5 | 8.5 | 59 | (19-137.7) | Male | 34 | 26.5 | 128.3 | (88.8-179.2) |
| Female | | | | | Female | 14 | 11.3 | 124.1 | (67.8-208.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 83 | 66.7 | 124.5 | (99.1-154.3) | Female | 26 | 21 | 123.7 | (80.8-181.3) |
| Female | 79 | 66.9 | 118.1 | (93.5-147.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 20 | 19.2 | 104.4 | (63.8-161.3) |
| Male | 20 | 16 | 124.8 | (76.2-192.7) | Female | 17 | 20.3 | 83.8 | (48.8-134.2) |
| Female | 1 | 4.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 270 | 226.7 | 119.1 | (105.3-134.2) |
| Male | 4 | 5.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 8 | 3.9 | 206.3 | (88.8-406.6) | Male | 18 | 13.9 | 129.3 | (76.6-204.4) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 8 | 8.2 | 98 | (42.2-193) |
| Male | 30 | 32.4 | 92.6 | (62.5-132.2) | <u>Testis</u> | | | | |
| Female | 18 | 18.3 | 98.3 | (58.2-155.4) | Male | 5 | 8.6 | 58.2 | (18.7-135.8) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 14 | 8.8 | 158.7 | (86.7-266.3) | Male | 19 | 14.8 | 128 | (77-199.8) |
| Female | 0 | 2.7 | nc | (nc-nc) | Female | 63 | 44.2 | 142.5 | (109.5-182.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 31 | 22.9 | 135.3 | (91.9-192.1) | Female | 50 | 53.8 | 93 | (69-122.6) |
| Female | 15 | 16.9 | 89 | (49.8-146.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 932 | 800.6 | 116.4 | (109.1-124.1) |
| Male | 19 | 18.9 | 100.5 | (60.5-157) | Female | 944 | 786.7 | 120 | (112.5-127.9) |
| Female | 7 | 6.3 | 111.5 | (44.7-229.8) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 112 | 105.8 | 105.9 | (87.2-127.4) | | | | | |
| Female | 129 | 108.5 | 118.9 | (99.3-141.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 2.8 | 217.9 | (79.6-474.2) | Male | 3 | 2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 4 | 1.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 10 | 11.4 | 88 | (42.1-161.9) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 0.4 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 3.3 | nc | (nc-nc) | Female | 0 | 1 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.9 | nc | (nc-nc) |
| Male | 2 | 0.8 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 15 | 12.5 | 120 | (67.1-197.9) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.3 | nc | (nc-nc) |
| Male | 1 | 1.7 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.8 | nc | (nc-nc) | Male | 2 | 0.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 2 | 2.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 43 | 41.5 | 103.7 | (75-139.7) |
| Male | 0 | 1 | nc | (nc-nc) | Female | 35 | 36 | 97.2 | (67.7-135.3) |
| Female | 1 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 3 | 5.3 | nc | (nc-nc) | | | | | |
| Female | 7 | 4.6 | 150.8 | (60.4-310.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|----------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 3.5 | 144.2 | (46.5-336.6) | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) | Female | 1 | 1.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 0.8 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 5 | 2.2 | 228.2 | (73.5-532.5) |
| Female | 14 | 14.4 | 97.1 | (53.1-163) | Female | 3 | 1.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 0.5 | nc | (nc-nc) | Male | 3 | 1.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 4.3 | nc | (nc-nc) | Female | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 3.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 1 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 27 | 15.8 | 171.3 | (112.9-249.2) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 2 | 2.2 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 5 | 1.1 | 475.4 | (153.2-1109.4) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 2 | 1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 4 | 2.9 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Female | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 3 | 6.7 | nc | (nc-nc) | Male | 61 | 52.6 | 115.9 | (88.6-148.8) |
| Female | 2 | 5.8 | nc | (nc-nc) | Female | 44 | 45.2 | 97.4 | (70.8-130.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 5.2 | nc | (nc-nc) | Male | 7 | 3.4 | 204.4 | (81.9-421.1) |
| Female | 2 | 1.6 | nc | (nc-nc) | Female | 4 | 2.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 1 | 1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 7 | 3 | 234.9 | (94.1-484) |
| Female | 29 | 16.7 | 173.7 | (116.3-249.5) | Female | 1 | 2.1 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 7 | 2.4 | 297.1 | (119-612.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 6.1 | 115.3 | (46.2-237.5) | Female | 3 | 1.5 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 1.7 | nc | (nc-nc) |
| Male | 3 | 1.4 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 16 | 20 | 80.1 | (45.8-130.1) |
| Male | 3 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 0.6 | nc | (nc-nc) |
| Male | 2 | 2.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 1.3 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 2.8 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.9 | nc | (nc-nc) | Female | 4 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 91 | 70.7 | 128.8 | (103.7-158.1) |
| Male | 4 | 1.7 | nc | (nc-nc) | Female | 71 | 57.7 | 123.1 | (96.2-155.3) |
| Female | 1 | 0.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 12 | 9.5 | 126.6 | (65.4-221.2) | | | | | |
| Female | 9 | 8.4 | 107.7 | (49.2-204.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 87 | 102.6 | 84.8 | (67.9-104.6) | Male | 63 | 66.6 | 94.7 | (72.7-121.1) |
| Female | 38 | 40.7 | 93.5 | (66.1-128.3) | Female | 62 | 56.5 | 109.7 | (84.1-140.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 16 | 19.4 | 82.4 | (47.1-133.9) | Male | 16 | 18.3 | 87.5 | (50-142.2) |
| Female | 10 | 17.1 | 58.5 | (28-107.6) | Female | 11 | 16.2 | 68 | (33.9-121.7) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 3 | 3.2 | nc | (nc-nc) | Male | 50 | 58.5 | 85.5 | (63.4-112.7) |
| Female | 387 | 405 | 95.6 | (86.3-105.6) | Female | 59 | 52.1 | 113.3 | (86.2-146.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 20 | 14.7 | 135.8 | (82.9-209.8) | Male | 64 | 42.9 | 149.1 | (114.8-190.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 139 | 115 | 120.8 | (101.6-142.7) | Female | 34 | 37.5 | 90.8 | (62.9-126.9) |
| Female | 140 | 128.1 | 109.3 | (92-129) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 33 | 27.1 | 121.9 | (83.9-171.3) | Male | 311 | 372.5 | 83.5 | (74.5-93.3) |
| Female | 10 | 8.2 | 121.5 | (58.2-223.4) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 6 | 8.7 | 68.9 | (25.2-150) | Male | 9 | 15.1 | 59.7 | (27.3-113.4) |
| Female | 6 | 7.3 | 81.8 | (29.9-178.1) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 55 | 53.5 | 102.8 | (77.5-133.8) | Female | 93 | 92.4 | 100.7 | (81.3-123.3) |
| Female | 36 | 33.1 | 108.6 | (76.1-150.4) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 15 | 14.7 | 101.7 | (56.9-167.7) | Male | 29 | 39.4 | 73.6 | (49.3-105.7) |
| Female | 5 | 4.8 | 103.2 | (33.3-241) | Female | 28 | 31.3 | 89.4 | (59.4-129.2) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 56 | 31.1 | 179.8 | (135.8-233.5) | Male | 204 | 185.3 | 110.1 | (95.5-126.3) |
| Female | 13 | 11.7 | 111.5 | (59.3-190.7) | Female | 243 | 205.4 | 118.3 | (103.9-134.2) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 27 | 32.9 | 82 | (54-119.2) | Male | 13 | 22 | 59.1 | (31.4-101) |
| Female | 9 | 12.3 | 73.3 | (33.4-139.2) | Female | 21 | 18.4 | 114 | (70.6-174.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 6.7 | 74.9 | (24.1-174.8) | Male | 7 | 6 | 116.1 | (46.5-239.3) |
| Female | 7 | 5.7 | 123.6 | (49.5-254.8) | Female | 9 | 5 | 180.5 | (82.4-342.7) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1 | nc | (nc-nc) | Male | 17 | 19.3 | 87.9 | (51.2-140.7) |
| Female | 125 | 135.1 | 92.5 | (77-110.2) | Female | 17 | 16.3 | 104.1 | (60.6-166.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 7 | 5 | 138.8 | (55.6-285.9) | Male | 8 | 14.8 | 53.9 | (23.2-106.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 40 | 37.9 | 105.5 | (75.4-143.7) | Female | 10 | 12.2 | 81.9 | (39.2-150.7) |
| Female | 43 | 39 | 110.3 | (79.9-148.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 17 | 11 | 155.2 | (90.4-248.6) |
| Male | 7 | 9 | 77.4 | (31-159.5) | Female | 11 | 11.8 | 93.1 | (46.4-166.6) |
| Female | 3 | 2.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 124 | 126.7 | 97.8 | (81.4-116.7) |
| Male | 1 | 2.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 2.4 | nc | (nc-nc) | Male | 5 | 7.9 | 63.2 | (20.4-147.4) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 6 | 4.8 | 126.1 | (46-274.4) |
| Male | 24 | 18.2 | 131.8 | (84.4-196.2) | <u>Testis</u> | | | | |
| Female | 10 | 10.7 | 93.6 | (44.8-172.1) | Male | 0 | 4.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 9 | 5 | 180.9 | (82.6-343.4) | Male | 4 | 8.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) | Female | 23 | 26.6 | 86.6 | (54.9-130) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 10 | 13.1 | 76.5 | (36.6-140.8) | Female | 31 | 30.9 | 100.3 | (68.1-142.4) |
| Female | 5 | 9.9 | 50.7 | (16.3-118.2) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 428 | 452.7 | 94.5 | (85.8-103.9) |
| Male | 14 | 10.7 | 131 | (71.5-219.7) | Female | 441 | 459.7 | 95.9 | (87.2-105.3) |
| Female | 7 | 3.7 | 191.3 | (76.7-394.3) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 61 | 60.5 | 100.9 | (77.2-129.6) | | | | | |
| Female | 54 | 63.7 | 84.8 | (63.7-110.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 18 | 14.3 | 126.3 | (74.8-199.6) | Male | 7 | 9.5 | 73.7 | (29.5-151.9) |
| Female | 5 | 5.2 | 97 | (31.2-226.3) | Female | 11 | 7.7 | 143.4 | (71.5-256.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.9 | nc | (nc-nc) | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) | Female | 3 | 2.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 5 | 8.3 | 60 | (19.3-140) |
| Female | 63 | 57.3 | 109.9 | (84.5-140.7) | Female | 8 | 6.9 | 116.5 | (50.1-229.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 6 | 2.1 | 285.7 | (104.3-621.9) | Male | 5 | 6.4 | 77.6 | (25-181.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 18 | 16.4 | 109.8 | (65.1-173.6) | Female | 3 | 5.2 | nc | (nc-nc) |
| Female | 20 | 16.4 | 122.3 | (74.7-188.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 4 | 3.9 | nc | (nc-nc) | Male | 65 | 55.3 | 117.5 | (90.7-149.8) |
| Female | 3 | 1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 3 | 1.2 | nc | (nc-nc) | Male | 6 | 1.9 | 319.6 | (116.7-695.6) |
| Female | 1 | 1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 16 | 7.9 | 202.6 | (115.7-329) | Female | 8 | 13.2 | 60.8 | (26.2-119.7) |
| Female | 8 | 4.5 | 177.3 | (76.4-349.5) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 1 | 2.2 | nc | (nc-nc) | Male | 5 | 5.6 | 89.1 | (28.7-207.9) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 5 | 4.1 | 121.3 | (39.1-283) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 4 | 4.6 | nc | (nc-nc) | Male | 34 | 26.2 | 129.6 | (89.8-181.2) |
| Female | 2 | 1.5 | nc | (nc-nc) | Female | 35 | 26.9 | 130.3 | (90.7-181.2) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 30 | 26.4 | 113.6 | (76.6-162.2) | Male | 27 | 17.4 | 155.5 | (102.5-226.3) |
| Female | 11 | 9.9 | 110.7 | (55.2-198.2) | Female | 18 | 14.1 | 127.6 | (75.6-201.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 5.2 | 115.1 | (42-250.5) | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 4.4 | 137 | (50-298.2) | Female | 4 | 4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 13 | 15.3 | 85 | (45.2-145.3) |
| Female | 135 | 106.3 | 127 | (106.4-150.3) | Female | 11 | 13 | 84.8 | (42.3-151.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 3.8 | nc | (nc-nc) | Male | 6 | 11.6 | 51.5 | (18.8-112.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 32 | 30.2 | 105.9 | (72.4-149.6) | Female | 5 | 9.6 | 52.2 | (16.8-121.8) |
| Female | 37 | 31.5 | 117.4 | (82.6-161.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 8 | 8.7 | 91.9 | (39.6-181.1) |
| Male | 8 | 7.2 | 111.8 | (48.2-220.4) | Female | 6 | 9.6 | 62.5 | (22.8-136.1) |
| Female | 3 | 2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 84 | 99.3 | 84.6 | (67.5-104.8) |
| Male | 2 | 2.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 4 | 1.7 | nc | (nc-nc) | Male | 7 | 6.3 | 111.1 | (44.5-228.9) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 3.9 | nc | (nc-nc) |
| Male | 12 | 14.4 | 83.5 | (43.1-145.8) | <u>Testis</u> | | | | |
| Female | 3 | 8.5 | nc | (nc-nc) | Male | 3 | 3.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 3.9 | nc | (nc-nc) | Male | 9 | 6.4 | 141.7 | (64.7-269) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 35 | 19.6 | 179 | (124.7-249) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 10.3 | 106.5 | (53.1-190.6) | Female | 32 | 24.2 | 132.4 | (90.5-186.9) |
| Female | 12 | 7.8 | 153.4 | (79.2-267.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 337 | 357.2 | 94.3 | (84.5-105) |
| Male | 5 | 8.4 | 59.4 | (19.1-138.6) | Female | 426 | 362.8 | 117.4 | (106.5-129.1) |
| Female | 6 | 2.9 | 205.1 | (74.9-446.5) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 48 | 48.2 | 99.6 | (73.4-132) | | | | | |
| Female | 50 | 51 | 98 | (72.7-129.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 10 | 11.5 | 87.2 | (41.8-160.4) | Male | 5 | 8.1 | 61.4 | (19.8-143.3) |
| Female | 4 | 3.7 | nc | (nc-nc) | Female | 4 | 6.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 46 | 47.1 | 97.8 | (71.6-130.4) | Female | 8 | 5.2 | 154.2 | (66.4-303.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.8 | nc | (nc-nc) | Male | 2 | 5.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 11 | 13.8 | 79.4 | (39.6-142.1) | Female | 2 | 4.1 | nc | (nc-nc) |
| Female | 10 | 12 | 83.6 | (40-153.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 2 | 3.4 | nc | (nc-nc) | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 5 | 3.5 | 142.7 | (46-332.9) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 1 | nc | (nc-nc) | Male | 54 | 49.6 | 108.9 | (81.8-142.1) |
| Female | 1 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 5 | 7.1 | 70.9 | (22.8-165.4) | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 5 | 3.5 | 141.1 | (45.5-329.4) | Female | 1 | 1.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 4.6 | nc | (nc-nc) | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) | Female | 8 | 9.4 | 85.4 | (36.8-168.2) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 4.2 | nc | (nc-nc) | Female | 15 | 10.8 | 138.3 | (77.4-228.2) |
| Female | 3 | 1.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 27 | 21.8 | 123.9 | (81.6-180.3) | Male | 146 | 168.7 | 86.5 | (73.1-101.8) |
| Female | 18 | 20 | 89.8 | (53.2-141.9) | Female | 146 | 151.6 | 96.3 | (81.3-113.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 46 | 54.6 | 84.2 | (61.7-112.3) | Male | 25 | 35.1 | 71.3 | (46.1-105.3) |
| Female | 21 | 20.5 | 102.7 | (63.5-156.9) | Female | 31 | 28.4 | 109 | (74.1-154.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 11 | 10.3 | 106.5 | (53.1-190.6) | Male | 10 | 9.7 | 103.6 | (49.6-190.6) |
| Female | 8 | 8.8 | 90.9 | (39.1-179.1) | Female | 12 | 8.1 | 147.6 | (76.2-257.8) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 1.7 | nc | (nc-nc) | Male | 26 | 30.9 | 84.1 | (54.9-123.2) |
| Female | 222 | 203.9 | 108.9 | (95-124.2) | Female | 34 | 26.3 | 129.4 | (89.6-180.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 6 | 7.5 | 80.5 | (29.4-175.2) | Male | 23 | 22.2 | 103.6 | (65.6-155.4) |
| Female | | | | | Female | 12 | 10.2 | 117.4 | (60.6-205) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 79 | 60.6 | 130.3 | (103.1-162.4) | Female | 16 | 18.8 | 85 | (48.5-138) |
| Female | 46 | 64.5 | 71.3 | (52.2-95.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 15 | 17.7 | 84.7 | (47.4-139.7) |
| Male | 8 | 14.2 | 56.5 | (24.3-111.2) | Female | 15 | 19.9 | 75.4 | (42.2-124.4) |
| Female | 5 | 4.2 | 120.3 | (38.8-280.7) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 132 | 193.3 | 68.3 | (57.1-81) |
| Male | 8 | 4.5 | 175.9 | (75.7-346.5) | <u>Stomach</u> | | | | |
| Female | 3 | 3.7 | nc | (nc-nc) | Male | 19 | 12.8 | 148.7 | (89.5-232.3) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 8 | 8 | 100.4 | (43.3-197.9) |
| Male | 35 | 28 | 125 | (87-173.8) | <u>Testis</u> | | | | |
| Female | 39 | 16.8 | 232.7 | (165.5-318.1) | Male | 11 | 7.8 | 140.7 | (70.1-251.8) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 14 | 7.7 | 181.6 | (99.2-304.8) | Male | 9 | 12.5 | 71.9 | (32.8-136.5) |
| Female | 8 | 2.4 | 328.8 | (141.6-647.9) | Female | 45 | 38.8 | 116 | (84.6-155.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 25 | 21.1 | 118.7 | (76.8-175.3) | Female | 35 | 46.3 | 75.6 | (52.7-105.2) |
| Female | 13 | 16 | 81 | (43.1-138.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 704 | 714.8 | 98.5 | (91.4-106) |
| Male | 29 | 16.2 | 179.6 | (120.2-257.9) | Female | 805 | 721.4 | 111.6 | (104-119.6) |
| Female | 6 | 5.9 | 102.2 | (37.3-222.4) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 122 | 98.1 | 124.4 | (103.3-148.5) | | | | | |
| Female | 160 | 103.7 | 154.3 | (131.3-180.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|--------------|--------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 2.5 | nc | (nc-nc) | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 1 | 1.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 8 | 8.5 | 93.8 | (40.4-184.8) | Female | 1 | 1 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2.8 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 5 | 2.3 | 213.7 | (68.9-498.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Stomach</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Leukemia</u> | | | | | <u>Male</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | 33 | 34.5 | 95.7 | (65.9-134.4) | |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Female</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>23</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | 28.3 | 81.2 | (51.4-121.8) | | |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Lung and Bronchus</u> | | | | |
| Male | 1 | 4.8 | nc | (nc-nc) | <u>Male</u> | | | | |
| Female | 2 | 4.1 | nc | (nc-nc) | <u>Female</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 5.1 | nc | (nc-nc) | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 3 | 2.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Male | 0 | 1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 24 | 21 | 114 | (73-169.7) | Female | 1 | 2.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 0.8 | nc | (nc-nc) | Male | 3 | 2.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 6.2 | nc | (nc-nc) | Female | 1 | 1.8 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 1.8 | nc | (nc-nc) |
| Male | 1 | 1.5 | nc | (nc-nc) | Female | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 30 | 22.5 | 133.5 | (90.1-190.6) |
| Male | 0 | 0.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.6 | nc | (nc-nc) |
| Male | 1 | 3.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 4 | 1.6 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 2 | 4.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 2.1 | nc | (nc-nc) | Female | 2 | 4.8 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 76 | 76.1 | 99.9 | (78.7-125) |
| Male | 1 | 1.9 | nc | (nc-nc) | Female | 60 | 66.9 | 89.6 | (68.4-115.4) |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 13 | 9.7 | 134 | (71.3-229.2) | | | | | |
| Female | 4 | 8.7 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 20 | 17.7 | 113.3 | (69.2-175) | Male | 10 | 11.8 | 84.9 | (40.6-156.1) |
| Female | 11 | 7 | 157.5 | (78.5-281.8) | Female | 18 | 10.2 | 176.1 | (104.3-278.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 7 | 3.6 | 194.4 | (77.9-400.5) | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) | Female | 1 | 2.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 13 | 10.4 | 125.5 | (66.8-214.7) |
| Female | 80 | 75.6 | 105.9 | (83.9-131.8) | Female | 11 | 9.2 | 119.4 | (59.5-213.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 2.8 | nc | (nc-nc) | Male | 7 | 7.9 | 88.7 | (35.5-182.7) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 24 | 20.2 | 118.7 | (76-176.6) | Female | 3 | 6.8 | nc | (nc-nc) |
| Female | 22 | 21.9 | 100.3 | (62.8-151.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 8 | 4.8 | 165.3 | (71.2-325.8) | Male | 77 | 67.8 | 113.6 | (89.6-141.9) |
| Female | 1 | 1.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 13 | 9.7 | 133.4 | (70.9-228) | Female | 19 | 17.4 | 109.2 | (65.7-170.6) |
| Female | 12 | 6 | 198.4 | (102.4-346.6) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 4 | 2.7 | nc | (nc-nc) | Male | 15 | 7 | 213.8 | (119.6-352.7) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 12 | 5.6 | 215.7 | (111.3-376.8) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 3 | 5.7 | nc | (nc-nc) | Male | 40 | 32.5 | 123.1 | (88-167.7) |
| Female | 3 | 2.1 | nc | (nc-nc) | Female | 48 | 36.6 | 131.1 | (96.7-173.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 16 | 11.4 | 140.1 | (80-227.5) | Male | 8 | 7 | 114.9 | (49.5-226.4) |
| Female | 6 | 4.5 | 132.9 | (48.5-289.2) | Female | 10 | 5.6 | 177.7 | (85-326.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 1.9 | nc | (nc-nc) | Male | 2 | 2 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) | Female | 3 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 3 | 0.4 | nc | (nc-nc) | Male | 7 | 6.1 | 114.5 | (45.9-235.9) |
| Female | 41 | 43.7 | 93.8 | (67.3-127.3) | Female | 6 | 5.6 | 106.8 | (39-232.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.4 | nc | (nc-nc) | Male | 6 | 4.6 | 130.8 | (47.8-284.7) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 12 | 12.6 | 95.5 | (49.3-166.9) | Female | 1 | 4 | nc | (nc-nc) |
| Female | 15 | 14 | 107.1 | (59.9-176.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 4 | 3.7 | nc | (nc-nc) |
| Male | 5 | 3 | 166.8 | (53.8-389.3) | Female | 4 | 4.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 42 | 41.6 | 100.9 | (72.7-136.5) |
| Male | 0 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 0 | 2.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 1.7 | nc | (nc-nc) |
| Male | 6 | 5.6 | 106.5 | (38.9-231.8) | <u>Testis</u> | | | | |
| Female | 2 | 3.6 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 8 | 6.8 | 117.2 | (50.5-231) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 4.1 | nc | (nc-nc) | Female | 10 | 10.3 | 97.4 | (46.6-179.2) |
| Female | 2 | 3.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 154 | 147.2 | 104.6 | (88.8-122.5) |
| Male | 2 | 3.4 | nc | (nc-nc) | Female | 143 | 153.4 | 93.2 | (78.6-109.8) |
| Female | 1 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 20 | 20.5 | 97.4 | (59.5-150.5) | | | | | |
| Female | 10 | 22.9 | 43.7 | (20.9-80.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 1 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 2 | 2.7 | nc | (nc-nc) |
| Male | 0 | 0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.1 | nc | (nc-nc) |
| Male | 0 | 0.4 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 8 | 9.2 | 86.6 | (37.3-170.7) |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 4 | 7.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 8 | 5.3 | 151.6 | (65.3-298.6) | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) | Female | 4 | 3.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 0 | 1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 2 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 26 | 23.3 | 111.6 | (72.8-163.5) | Female | 3 | 2.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 0.9 | nc | (nc-nc) | Male | 4 | 2.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 4 | 6.5 | nc | (nc-nc) | Female | 1 | 2.1 | nc | (nc-nc) |
| Female | 7 | 6.3 | 111.5 | (44.7-229.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 4 | 1.8 | nc | (nc-nc) |
| Male | 6 | 1.6 | 385.7 | (140.8-839.5) | Female | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 26 | 22.4 | 116.3 | (75.9-170.4) |
| Male | 1 | 0.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 0.8 | nc | (nc-nc) |
| Male | 3 | 3.3 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 4 | 1.8 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 5 | 4.7 | 106.7 | (34.4-249.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.2 | nc | (nc-nc) | Female | 5 | 5.2 | 95.6 | (30.8-223.1) |
| Female | 0 | 1.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 80 | 77.9 | 102.7 | (81.4-127.8) |
| Male | 0 | 1.9 | nc | (nc-nc) | Female | 77 | 76 | 101.3 | (79.9-126.6) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 7 | 9.9 | 70.6 | (28.3-145.5) | | | | | |
| Female | 6 | 9.9 | 60.9 | (22.2-132.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 1 | 1 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 6 | 5 | 121 | (44.2-263.3) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 5 | 5.9 | 84.6 | (27.3-197.5) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Female | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 2 | 2.1 | nc | (nc-nc) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;